Use of a CD28 binding substance for the production of a pharmaceutical composition with dose-dependent efficacy

Using CD28-specific super agonistic monoclonal antibodies (mAb) or their mimicry compounds (A) for preparing a pharmaceutical composition (I) for treatment or prophylaxis of autoimmune mediated inflammatory diseases or immune regeneration, is new. Using CD28-specific super agonistic monoclonal antibodies (mAb) or their mimic compounds (A) for preparing a pharmaceutical composition (I) for treatment or prophylaxis of autoimmune mediated inflammatory diseases or immune regeneration, is new. (I), under standard conditions, is prepared so that the dose of mAb lies below a defined first border dose when the treatment or prophylaxis of autoimmune inflammatory disease is indicated and the dose of mAb lies above a defined second border dose when the immune reconstitution is indicated. An independent claim is also included for treating or prophylaxis of autoimmune mediated inflammatory diseases comprising: (a) administering (I) (containing (A) and galenic preparation for a definite and applied pharmaceutical form), preferably via intravenous injection, to a patient; or (b) removing a body fluid (preferably blood) containing T-lymphocytes or their precursor cells, treating with (by appropriate process) (A) and administering thus treated body fluid (preferably via intravenous injection) to the patient. ACTIVITY : Antiinflammatory; Immunosuppressive; Antiarthritic; Antirheumatic; Neuroprotective; Antidiabetic; Antipsoriatic; CNS-Gen.; Cytostatic; Anti-HIV; Virucide. No biological data is given. MECHANISM OF ACTION : Cluster of differentiation-28 (CD28) specific super agonist.